AH
Therapeutic Areas
Puma Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NERLYNX (neratinib, oral) | Extended adjuvant treatment of HER2-positive early breast cancer | Approved |
| Alisertib | 3rd-line+ Extensive-Stage Small Cell Lung Cancer (SCLC) | Phase 3 |
Leadership Team at Puma Biotechnology
RJ
Robert J. Charnas
Chief Financial Officer
DT
David T. Tarlowe
Senior Vice President, General Counsel, and Corporate Secretary
DD
Dr. David S. Hong
Senior Vice President, Clinical Development
DT
Dr. Timothy P. Clackson
Senior Vice President, Research and Development